A systematic review of drug therapy to delay or prevent type 2 diabetes

Diabetes Care

Volumn 28, Issue 3, 2005, Pages 736-744

  Padwal, Raj ^a,c   Majumdar, Sumit R ^a,b   Johnson, Jeff A ^a,b   Varney, Janice ^b   McAlister, Finlay A ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSTITUTE OF HEALTH ECONOMICS   (Canada)

^c UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FIBRIC ACID DERIVATIVE; HYDROCHLOROTHIAZIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PHENFORMIN; PIOGLITAZONE; PRAVASTATIN; PROGESTERONE; ROSIGLITAZONE; STATINE DERIVATIVE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; TOLBUTAMIDE; TRANDOLAPRIL; TROGLITAZONE; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; ESTROGEN THERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INCIDENCE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LACTONES; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS;

EID: 14644418458     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.3.736     Document Type: Review

References (57)

1. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053, 2004
2. American Diabetes Association: Economic costs of diabetes in the U.S. in 2002. Diabetes Care 26:917-932, 2003
3. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
4. The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
5. Touyz R, Campbell N, Logan A, Gledhill N, Petrella R, Padwal R: The 2004 Canadian recommendations for the management of hypertension. III. Lifestyle modifications to prevent and control hypertension. Can J Cardiol 20:55-59, 2004
6. Goldstein DJ: Beneficial effects of modest weight loss. Int J Obes Relat Metab Disord 16:397-415, 1992
7. Hooper L, Summerbell CD, Higgins JPT, Thompson RL, Clements G, Capps N, Davey S, Riemersma RA, Ebrahim S: Reduced or modified dietary fat for preventing cardiovascular disease (Cochrane Review). In The Cochrane Library. Issue 2. Chichester, U.K., John Wiley & Sons, 2004
8. NIH Technology Assessment Conference Panel: Methods for voluntary weight loss and control. Ann Intern Med 119:764-770, 1993
9. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Disease: The prevention or delay of type 2 diabetes. Diabetes Care 25:742-749, 2002
10. Davies MJ, Tringham JR, Troughton J, Khunti KK: Prevention of Type 2 diabetes mellitus: a review of the evidence and its application in a UK setting. Diabet Med 21:403-414, 2004
11. Padwal R, Laupacis A: Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 27: 247-255, 2004
12. The Diabetes Prevention Program Research Group: Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 26:977-980, 2003
13. Yang W, Lin L, Qi J: The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: a 3-year multicentre prospective study. Chin J Endocrinol Metab 17:131-136, 2001
14. Li CL, Pan CY, Lu JM, Zhu Y, Wang JH, Deng XX, Xia FC, Wang HZ, Wang HY: Effect of metformin on patients with impaired glucose tolerance. Diabet Med 16: 477-481, 1999
15. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, Andre P, Isnard F, Cohen JM, Grandmottet P, Vague P, Safar ME, Eschwege E: The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 19:920-926, 1996
16. Jarrett RJ, Keen H, Fuller JH, McCartney M: Worsening to diabetes in men with impaired glucose tolerance ('borderline diabetes'). Diabetologia 16:25-30, 1979
17. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359:2072-2077, 2002
18. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486-494, 2003
19. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G: Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 29:41-49, 1980
20. Keen H, Jarrett RJ, Ward JD, Fuller JH: Borderline diabetics and their response to tolbutamide. Adv Metab Disord 2 (Suppl. 2):521-531, 1973
21. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic B-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51: 2796-2803, 2002
22. Durbin RJ: Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 6:280-285, 2004
23. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:155-161, 2004
24. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JP, Sjostrom L: Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 160:1321-1326, 2000
25. Savage PH, Pressel SL, Curb D, Schron EB, Applegate WB, Black HR, Cohen J, Davis BR, Frost P, Smith W, Gonzalez N, Guthrie GP, Oberman A, Rutan G. Probstfield JL, Stamler J: Influence of long-term, low-dose, diuretic-based antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Arch Intern Med 158:741-751, 1998
26. Fletcher A, Amery A, Birkenhager W, Bulpitt C, Clement D, de Leeuw P, Deruyterre ML, de Schaepdryver A, Dollery C, Fagard R, Forette F, Forte J, Henry JF, Koistinen A, Leonetti G, Lund-Johansen P, Nissinen A, O'Brien E, O'Malley K, Pelemans W, Petrie J, Staessen J, Terzoli L, Thijs L, Tuomilehto J, Webster J, Williams B: Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly. J Hypertens 9:225-230, 1991
27. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BHR, Zinman B: Ramipril and the development of diabetes. JAMA 286:1882-1885, 2001
28. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC: Enalapril reduces the incidence of diabetes in patients with chronic heart failure. Circulation 107:1291-1296, 2003
29. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J, Yusuf S: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362:759-766, 2003
30. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A: The Study on Cognition and Prognosis in the Elderly (SCOPE): principle results of a randomized double-blind intervention trial. J Hypertens 21:875-886, 2003
31. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290:2805-2816, 2003
32. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Tsushung H, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, the VALUE Trial Group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363:2022-2031, 2004
33. Freeman DJ, Norrie J, Sattar N, Neely DG, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357-362, 2001
34. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361: 2005-2016, 2003
35. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Diabetes Care 26:2713-2721, 2003
36. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158, 2003
37. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S: Peroxisome proliferators-activated receptor ligand Bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109: 2197-2202, 2004
38. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Conner E: Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study. Ann Intern Med 138:1-9, 1992
39. Manson JE, Rimm EB, Colditz GA, Willett WC, Nathan DM, Arky RA, Rosner B, Hennekens CH, Speizer FE, Stampfer MJ: A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol 2:665-673, 1992
40. Rossi R, Origliani G, Modena MG: Transdermal 17-B-Estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care 27:645-649, 2004
41. Zhang Y, Howard BV, Cowan LD, Yeh J, Schaefer CF, Wild RA, Wang W, Lee ET: The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in American Indian postmenopausal women. Diabetes Care 25:500-504, 2002
42. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT: Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol 133: 525-536, 1997
43. Gabal LL, Goodman-Gruen D, Barrett-Connor E: The effect of postmenopausal estrogen therapy on the risk of non-insulin-dependent diabetes mellitus. Am J Public Health 87:443-445, 1997
44. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: The Da Qing IGT, Diabetes Study. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care 20:537-544, 1997
45. UK Prospective Diabetes Study Group: UK prospective diabetes study 16: overview of 6 years' therapy of type II diabetes. Diabetes 44:1249-1258, 1995
46. Yee A, Majumdar SR, Simpson SH, McAlister FA, Tsuyuki RT, Johnson JA: Statin use in type 2 diabetes mellitus is associated with a delay in starting insulin. Diabet Med 21:962-967, 2004
47. Herlihy OM, Morris RJ, Karunakaran S, Holman R: Sulfonylurea therapy over six years does not delay progression to diabetes (Abstract). Diabetologia 43 (Suppl. 1): A73, 2000
48. Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL: Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 95:272-276, 2000
49. The Diabetes Prevention Program Research Group: Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 26:2518-2523, 2003
50. Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ: Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the Diabetes Prevention Program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther 26:304-321, 2004
51. Holman RR, Blackwell L, Stratton IM, Manley SE, Tucker L, Frighi V: Six-year results from the Early Diabetes Intervention Trial (Abstract). Diabet Med 20 (Suppl. 2):S15, 2003
52. Lindblad U, Lindwall K, Sjostrand A, Ranstam J, Melander A: The NEPI Antidiabetes Study (NANSY). I. Short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose. Diabetes Obes Metab 3:443-451, 2001
53. The Oxford Center for Diabetes Endocrinology and Metabolism. DREAM overview [article online], 2002. Available from http://www.dtu.ox.ac.uk/index. html? maindoc=/dream. Accessed 24 September 2004
54. Navigator press release: the NAVIGATOR study [article online], 2001. Available from http://www.bioportfolio.com/news/novartis_2.htm. Accessed 24 September 2004
55. Yusuf S: From the HOPE to the ON-TARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 89 (Suppl.):18A-26A, 2002
56. Aventis press release: Aventis announces five-year ORIGIN trial to investigate reduction in heart disease risk with LANTUS insulin [article online], 2004. Available from http://www.aventis.com/main/page. asp?pageid=24322020040216162854& lang=en. Accessed 24 September 2004
57. Canadian Diabetes Association Website: Canadian Normoglycemic Outcomes Evaluation trial [article online], 2004. Available from http://www.diabetes.ca/ Section_Professionals/canoe_trial.asp. Accessed 22 November 2004